GleamWall
中文EN

ATYR aTYR PHARMA INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1339970 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-19.1%
TTM net income YoY-15.8%
TTM EPS YoY7.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-40,856.3%
Net margin-39,009.5%
FCF margin-32,664.7%
EBITDA margin-40,506.8%

Returns

ROE-107.8%
ROA-78.1%
ROIC (approx.)-106.0%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets27.6%
Debt / equity0.00x
Current ratio5.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-12.8%
Payout ratio—
Capex / revenue40.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0——$0$190,000$0$0$0
R&D expense$10.45M$6.75M$7.32M$10.89M$22.13M$15.38M$11.81M$12.23M
SG&A expense$8.35M$4.13M$4.12M$3.90M$4.80M$4.93M$3.96M$3.59M
Operating income-$18.79M-$10.88M-$11.44M-$14.80M-$26.75M-$20.31M-$15.77M-$15.82M
Net income-$18.26M-$10.31M-$10.79M-$13.96M-$25.74M-$19.53M-$14.88M-$14.97M
EBITDA-$18.62M-$10.71M-$11.27M-$14.63M-$26.58M-$20.15M-$15.61M-$15.64M
EPS (basic)-7.43-0.11-0.11—-10.60-0.22-0.17—
EPS (diluted)-7.43-0.11-0.11—-10.60-0.22-0.17—
Weighted avg. shares (diluted)2.46M98.07M98.04M—2.43M90.12M86.49M—
Balance sheet
Cash & equivalents$13.14M$16.16M$10.01M$10.74M$6.15M$17.22M$10.36M$11.05M
Short-term investments$35.61M$41.26M$56.51M$67.94M$79.00M$63.13M$65.99M$61.07M
Current assets$50.16M$58.36M$67.58M$80.24M$93.01M$87.49M$83.27M$81.95M
PP&E, net$3.38M$4.13M$4.24M$4.26M$4.43M$4.53M$4.68M$4.85M
Total assets$59.81M$69.83M$79.65M$93.00M$106.65M$101.53M$97.25M$96.83M
Current liabilities$16.46M$11.40M$11.70M$15.15M$15.68M$15.53M$10.68M$14.97M
Total liabilities$26.01M$21.23M$21.91M$25.71M$26.61M$26.88M$22.38M$27.00M
Shareholders' equity$33.98M$48.79M$57.93M$67.48M$80.23M$74.84M$75.05M$70.02M
Shares outstanding2.51M98.09M98.05M2.45M97.99M92.87M89.00M84.04M
Cash flow statement
Operating cash flow-$9.51M-$9.35M-$12.52M-$12.20M-$20.48M-$13.89M-$15.42M-$13.13M
Capital expenditure$45,000$73,000$138,000$31,000$37,000$9,000$0$25,000
Free cash flow-$9.56M-$9.42M-$12.65M-$12.23M-$20.51M-$13.90M-$15.42M-$13.16M
Investing cash flow$5.72M$15.32M$11.49M$16.44M-$20.38M$3.30M-$4.42M-$6.08M
Financing cash flow$773,000-$129,000-$142,000-$131,000$29.62M$17.90M$18.63M$18.84M
Depreciation & amortization$171,000$168,000$162,000$166,000$165,000$166,000$167,000$175,000
Stock-based compensation$2.59M$1.15M$1.31M$1.21M$1.31M$1.30M$1.18M$770,000

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.